89Zr-belantamab imaging to detect Myeloma (MAGNETO)

Research summary

This is a non-therapeutic experimental pilot study which aims to recruit up to 19 patients within England. Participants will be identified and approached by a healthcare professional that is part of their clinical care team within the haematology department at Churchill Hospital,Oxford. This study aims to develop 89Zr-belantamab as a PET imaging agent to image BCMA on myeloma cell infiltration. If the imaging agent can reliably demonstrate myeloma deposits,it has several potential applications for drug development and clinical use. Further studies could explore the following objectives For BCMA targeted therapies: • Demonstrate biodistribution and tissue/organ kinetics of belantamab • Help inform dosing and scheduling of therapies. • Understand effect of sBCMA on the PK of BCMA targeted therapies. • Stratification and selection of patients for BCMA targeted therapies by: - Assessing levels of BCMA expression in myeloma infiltration - Assess heterogeneity of BCMA expression in myeloma infiltration. For clinical use and understanding of biology of myeloma: • Detection of myeloma • Diagnose high risk cohorts with pre-myeloma conditions – in smouldering myeloma and MGUS leading to earlier detection and treatment of myeloma patients. • Assessment of disease burden • Better the understanding of sBCMA and other biomarkers in relation to lesion target expression • Response assessment of myeloma • Prognostication. The study has two parts. The first part (Part 1A and 1B) has the aim of optimising the methodology of scanning with 89Zr-Belantamab and will recruit up to 10 patients. The second part (Part 2) will incorporate information derived from the first part to use an optimised imaging protocol to investigate the target binding of different dose levels of belantamab and will recruit up to 9 new patients.

Principal Investigator

Dr Karthik Ramasamy

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1007735